Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 298

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

Spielmann, Marc, Roché, Henri, Delozier, Thierry, Canon, Jean-Luc, Romieu, Gilles, Bourgeois, Hugues, Extra, Jean-Marc, Serin, Daniel, Kerbrat, Pierre, Machiels, Jean-Pascal, Lortholary, Alain, Orfeuvre, Hubert, Campone, Mario, Hardy-Bessard, Anne-Claire, Coudert, Bruno, Maerevoet, Marie, Piot, Gilles, Kramar, Andrew, Martin, Anne-Laure, Penault-Llorca, Frédérique · 2009 · Journal of Clinical Oncology

Abstract

Purpose: To evaluate the efficacy of trastuzumab in patients with node-positive breast cancer treated with surgery, adjuvant chemotherapy, radiotherapy, and hormone therapy if applicable. Patients and Methods: Three thousand ten patients with operable node-positive breast cancer were randomly assigned to receive adjuvant anthracycline-based chemotherapy with or without docetaxel. Patients who presented human epidermal growth factor receptor 2 (HER2) -overexpressing tumors were secondary randomly assigned to either a sequential regimen of trastuzumab (6 mg/kg every 3 weeks) for 1 year or observation. The primary end point was disease-free survival (DFS). Results: Overall 528 patients were randomly assigned between trastuzumab (n = 260) and observation (n = 268) arm. Of the 234 patients (90%) who received at least one administration of trastuzumab, 196 (84%) received at least 6 months of treatment, and 41 (18%) discontinued treatment due to cardiac events (any grade). At the date of analysis (October 2007), 129 DFS events were recorded. Random assignment to the trastuzumab arm was associated with a nonsignificant 14% reduction in the risk of relapse (hazard ratio, 0.86; 95% CI, 0.61 to 1.22; P = .41, log-rank stratified on pathologic node involvement). Three-year DFS rates were 78% (95% CI, 72.3 to 82.5) and 81% (95% CI, 75.3 to 85.4) in the observation and trastuzumab arms, respectively. Conclusion: After a 47-month median follow-up, 1 year of trastuzumab given sequentially after adjuvant chemotherapy was not associated with a statistically significant decrease in the risk of relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.0946

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 298

Metadata

Authors
Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., Lortholary, A., Orfeuvre, H., Campone, M., Hardy-Bessard, A.-C., Coudert, B., Maerevoet, M., Piot, G., Kramar, A., Martin, A.-L., & Penault-Llorca, F.
Venue
Journal of Clinical Oncology
Published
2009-12-20
Volume
27
Issue
36
Pages
6129-6134
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2096818458
Cited by
298
References
18
FWCI
12.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial. https://app.cochat.ai/papers/10.1200/jco.2009.23.0946
The paper
Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., Lortholary, A., Orfeuvre, H., Campone, M., Hardy-Bessard, A.-C., Coudert, B., Maerevoet, M., Piot, G., Kramar, A., Martin, A.-L., & Penault-Llorca, F. (2009). Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.23.0946

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.